Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LGC Acquires Quotient’s Bioanalytical Business

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Acquisition will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector.

LGC and Quotient Bioresearch has announced that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.

Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.

The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.

Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences.

This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling.

The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.

The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.

Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”

Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quotient Clinical Reports Another Successful Year of Record Growth
Operating capacity set to more than double in response to rising demand.
Wednesday, May 13, 2015
Quotient Clinical and Bend Research Announce Collaboration to Accelerate Advancement of new Medicines
Complementary capabilities will cut development time and expand options for a wide range of drugs.
Thursday, November 11, 2010
Quotient Bioresearch Announce Collaboration with Clinical Reference Laboratory
The Collaborators will jointly offer clinical laboratory and other specialist testing services to support the two Group’s clients world wide.
Tuesday, August 25, 2009
Quotient Clinical Receives MHRA Supplementary Accreditation
Accreditation qualifies Quotient Clinical to perform FIH studies for low molecular weight chemical entities and biologics.
Friday, July 10, 2009
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories
The Charles River facility will combine with Pharmaceutical Profiles to form a new strategic business unit, Quotient Clinical.
Thursday, May 21, 2009
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!